Carisma Therapeutics Inc (CARM) concluded trading on Wednesday at a closing price of $0.50, with 4.1 million shares of worth about $2.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.94% during that period and on January 29, 2025 the price saw a gain of about 0.94%. Currently the company’s common shares owned by public are about 41.75M shares, out of which, 21.84M shares are available for trading.
Stock saw a price change of 14.65% in past 5 days and over the past one month there was a price change of 14.19%. Year-to-date (YTD), CARM shares are showing a performance of 20.51% which decreased to -76.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.38 but also hit the highest price of $2.77 during that period. The average intraday trading volume for Carisma Therapeutics Inc shares is 275.08K. The stock is currently trading 7.28% above its 20-day simple moving average (SMA20), while that difference is down -15.35% for SMA50 and it goes to -51.22% lower than SMA200.
Carisma Therapeutics Inc (NASDAQ: CARM) currently have 41.75M outstanding shares and institutions hold larger chunk of about 11.20% of that.
The stock has a current market capitalization of $21.08M and its 3Y-monthly beta is at 1.62. It has posted earnings per share of -$1.56 in the same period. It has Quick Ratio of 3.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CARM, volatility over the week remained 7.83% while standing at 11.61% over the month.
Stock’s fiscal year EPS is expected to rise by 53.67% while it is estimated to increase by 48.12% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on December 12, 2024 offering a Neutral rating for the stock and assigned a target price range of between $10 and $1 to it. On April 11, 2024, BTIG Research Initiated their recommendations, while on October 03, 2023, CapitalOne Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from Evercore ISI on July 06, 2023.
